At a glance
- Originator Merck & Co
- Class Anti-inflammatories
- Mechanism of Action Caspase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 11 Jun 2001 No-Development-Reported for Inflammation in USA (Unknown route)
- 21 Feb 1995 Preclinical development for Inflammation in USA (Unknown route)